Carnegie Mellon’s Joel McManus and Pitt’s Robert Nicholls received a $162,000 grant from the Foundation for Prader-Willi Research to study the regulation and function of a key gene that is usually ...
Phase 1/2 study initiated for ATX-559, a first-in-class inhibitor of DHX9, focused on patients with BRCA1/2-deficient breast cancer and MSI-H and/or dMMR ...